Investigation of the central nervous system sensitivity to drugs and psychiatric disorders

 

Among various promising applications, simultaneous MRI-PET appears extremely appealing for the study of neuropsychiatric diseases and pharmacology of central nervous system (CNS) drugs. Such studies are currently performed using separate PET and MR imaging and may be advantageously combined to provide new insight in the understanding of brain function in each individual. In each patient, the relationships between the molecular targets of neurotransmitters and drugs and their subsequent effects on the brain regions could be elucidated by the synchronicity of imaging acquisition, providing simultaneous molecular, functional, and structural information. Researchers, physicians and pharmacologists will mainly focus on high priority medical issues, including children epilepsy, mental disorders, addiction and pharmacoresistance. They will benefit from the complementary expertise of the PIM consortium to make the best with MRI-PET brain imaging.

 

Partners:

 

 

 

 

 

Project Leader: Jean-Luc Martinot (Inserm U1000)

 

• Pharmacological PET-MRI (N. Tournier - CEA SHFJ)

• Define PET data modeling (M. Bottlaender - CEA Neurospin)

• Brain PET-fMRI stimulation in mental disorders (E. Artiges - Inserm U1000)

• Paediatric epilepsy (C. Chiron - Inserm U633)